Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial
Primary result · 28-day survival in targeted subpopulation (PT-INR > 1.4 or lactate > 3 mmol/L), EUPHRATES cohortResult — go to the resultTreatment effect + 16% 95% CI + 2.2% to + 30%Authors' conclusion
Abnormal coagulation and hyperlactatemia in septic patients with high endotoxin activity appear to be helpful to identify patients who may benefit most from PMX-HA.
Study context
- Population
- Patients with sepsis (JSEPTIC-DIC, Japan) and endotoxemic septic shock with high endotoxin activity (EUPHRATES, North America)1,911 JSEPTIC-DIC
- Comparison
- PMX-HA vs control in the targeted subpopulation
- Primary endpoint
- 28-day survival
- Follow-up
- 28 days
Methodological detailsmachine learning-based causal forest model, derivation (JSEPTIC-DIC) and validation (EUPHRATES) cohorts, subgroup analysis
- Machine learning-based causal forest model
- Derivation (JSEPTIC-DIC) and validation (EUPHRATES) cohorts
- Subgroup analysis
Primary result
As reported in the abstract
28-day survival in targeted subpopulation (PT-INR > 1.4 or lactate > 3 mmol/L), EUPHRATES cohort
Treatment effect
+ 16%
95% CI + 2.2% to + 30%
P = 0.02
By group
Original publication
Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial. Crit Care. Published 21 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →